Pfizer Inc has signalled its determination to stay ahead in oncology by agreeing to pay Merck KGaA up to $2.85 billion for rights to the German company’s early-stage checkpoint inhibitor and collaborate on up to 20 other immuno-oncology programmes. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals